Search

Displaying results 2071 - 2080 of 4600 in total
  1. Drug

    Thrombin

    go.drugbank.com/drugs/DB11300
    ApprovedInvestigational

    Medical thrombin is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin in the presence of calcium chloride.

  2. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    agents that are metabolized by CYP3A enzymes. … Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered

  3. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that...

  4. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  5. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for … Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza.

  6. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.

  7. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI)
  8. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.

  9. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

    Salts: UM-171 dihydrobromide dihydrate
  10. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...